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Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk
patients with recent ischemic stroke or transient ischemic attack: rationale and
design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke
(TARDIS) trial (ISRCTN47823388)
The TARDIS Trial Investigators*
Rationale The risk of recurrence following a stroke or transient
ischemic attack is high, especially immediately after the event.
Hypothesis Because two antiplatelet agents are superior to
one in patients with non-cardioembolic events, more intensive
treatment might be even more effective.
Sample size estimates The sample size of 4100 patients will
allow a shift to less recurrence, and less severe recurrence,
to be detected (odds ratio 0·68) with 90% power at 5%
significance.
Methods and design Triple Antiplatelets for Reducing Depen-
dency after Ischaemic Stroke (ISRCTN47823388) is comparing
the safety and efficacy of intensive (combined aspirin, clopi-
dogrel, and dipyridamole) vs. guideline antiplatelet therapy,
both given for one-month. This international collaborative
parallel-group prospective randomized open-label blinded-
end-point phase III trial plans to recruit 4100 patients with
acute ischemic stroke or transient ischemic attack. Randomiza-
tion and data collection are performed over a secure Internet
site with real-time data validation and concealment of alloca-
tion. Outcomes, serious adverse events, and neuroimaging are
adjudicated centrally with blinding to treatment allocation.
Study outcome The primary outcome is stroke recurrence and
its severity (‘ordinal recurrence’ based on modified Rankin
Scale) at 90 days, with masked assessment centrally by tele-
phone. Secondary outcomes include vascular events, func-
tional measures (disability, mood, cognition, quality of life),
and safety (bleeding, death, serious adverse events).
Discussion The trial has recruited more than 50% of its target
sample size (latest number: 2399) and is running in 104 sites in
4 countries. One-third of patients presented with a transient
ischemic attack.
Key words: acute stroke, aspirin, clopidogrel, dipyridamole, randomized
controlled trial, transient ischemic attack
Introduction and rationale
Following stroke or transient ischemic attack (TIA), the risk of
recurrence is very high over the first few hours and days, reaching
10·3% by three-months (1,2). Risk then declines and totals about
40% by five-years. Importantly, recurrent strokes are usually more
severe than first events and so are more likely to lead to depen-
dency, cognitive impairment and dementia, depression, poor
quality of life, and need for long-term institutional care (3,4).
The long-term risk of recurrence can be reduced, but not abol-
ished, with lifestyle changes (reducing weight, saturated fat, salt
and high alcohol intake, and stopping smoking) and evidence-
based and cost-effective clinical interventions including lowering
blood pressure (BP) (all stroke and TIA) and lipids (ischemic
stroke and TIA), and carotid endarterectomy (large artery isch-
emic stroke and TIA) (1,2,5–10). While oral anticoagulants are
established therapy after cardioembolic stroke and TIA (11–14),
the majority of patients with acute and chronic ischemic stroke or
TIA need antiplatelets (15–23).
Antiplatelet therapy for acute ischemic stroke is based on
aspirin alone as a result of the IST-1 and CAST mega-trials
(17,18), although the effect size for improving functional
outcome was small (absolute risk reduction ∼1·1%), mostly
explained by aspirin reducing early recurrence. Until recently, the
acute treatment of TIA had not been investigated. Early and
short-term use of two agents appears to be superior to mono-
therapy, as suggested by observational studies (EXPRESS, SOS
(1,2)), small trials (FASTER, EARLY) (24,25), and a post hoc
subgroup analysis of the PRoFESS mega-trial (26). These findings
were strengthened by the large CHANCE trial that showed that
the combination of aspirin + clopidogrel was superior to aspirin
alone in reducing stroke recurrence (23). Indeed, it appears in
meta-analyses that any pair of antiplatelets is superior to any
single agent (27,28). A potential advantage of multi-antiplatelet
therapy is that it will help cover treatment resistance seen with
monotherapy for either aspirin or clopidogrel (29–31).
The situation in acute stroke and TIA differs from chronic
stroke (long-term secondary prophylaxis) where dual therapy
with aspirin + dipyridamole reduced events by 23% in compari-
son with aspirin or dipyridamole alone without increasing the
risk of bleeding (ESPS-2, ESPRIT) (19,21). However, dual
therapy based on aspirin + clopidogrel was not superior to
monotherapy with either agent alone (CHARISMA, MATCH)
(32,33). In MATCH, dual therapy caused more bleeding than
clopidogrel alone but without a significant reduction in recur-
rence (33,34).
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If dual therapy is more effective at preventing recurrence than
monotherapy for acute prophylaxis, then intensive therapy with
triple antiplatelets (combined aspirin + clopidogrel + dipyrida-
mole) may be better still, provided the risk of recurrence is high
and bleeding does not become excessive. We have performed a
series of ‘proof-of-mechanism’ and ‘proof-of-concept’ laboratory
studies and clinical trials investigating this approach (35–39). In
vitro studies starting in 2000 found that triple therapy was most
effective in inhibiting platelet aggregation, platelet–leucocyte con-
jugation, and leucocyte activation (35–37). In multiway crossover
phase I and II trials, short-term administrations of mono
(aspirin, clopidogrel, or dipyridamole), dual (combinations of
aspirin and clopidogrel, aspirin and dipyridamole, or clopidogrel
and dipyridamole), and triple (combined aspirin, clopidogrel,
and dipyridamole) antiplatelet therapy were compared; the com-
bination of aspirin and clopidogrel, with or without dipyrida-
mole, was most potent in inhibiting platelet function ex vivo in
both normal volunteers and participants with previous stroke/
TIA (38,39). (Of note, the platelet function tests used in these
studies are relatively insensitive to the intracellular effects of
dipyridamole.) In the only parallel group trial of intensive/triple
therapy in participants with stroke, we found that combined
aspirin, clopidogrel, and dipyridamole (vs. aspirin alone, chosen
because it was the UK standard of care at the time) was feasible to
administer in a pilot trial for up to 24 months (40). However, the
trial was stopped early on publication of ESPRIT (21) confirming
the superiority of combined aspirin and dipyridamole over
aspirin alone. There was a non-significant trend to increased
bleeding with triple antiplatelet therapy vs. aspirin alone.
Although unintended, the participants were at low risk of recur-
rence (young/recruited months after the event/many lacunar
strokes) (40), a problem also seen in MATCH and CHARISMA
(32,33). The study concluded that future trials of combined
aspirin, clopidogrel, and dipyridamole needed to target partici-
pants at high risk of recurrence and for a short treatment dura-
tion to minimize bleeding, so that benefit is likely to outweigh
hazard. Clinical use of triple antiplatelet therapy has also been
reported in a case series (41).
The TARDIS trial was designed to build on these laboratory
and clinical studies and aims to test the overall safety and efficacy
of intensive antiplatelet therapy with three agents in comparison
with guideline treatment.
Primary research question
Is intensive antiplatelet therapy (combined aspirin, clopidogrel,
and dipyridamole) safe and effective in reducing recurrence and
its severity at three-months, as compared with guideline anti-
platelet therapy (clopidogrel, or combined aspirin and dipyrida-
mole), when given acutely after stroke or TIA for one-month?
Methods
¶ refers to a change from the current Protocol version 1·5 (down-
loadable from http://www.nets.nihr.ac.uk/projects/hta/1010424).
Design
TARDIS is an international collaborative multicenter parallel-
group prospective randomized open-label blinded-end-point
phase III controlled trial.
Patient population
Inclusion criteria:
• Age ≥50 years
• Event to randomization ≤48 h (24–48 h if thrombolysed)
• Index event is a TIA (defined in supplement of Statistical
Analysis Plan (42)) with:
○ Resolved limb weakness and/or dysphasia
○ Duration 10 min to <24 h
○ ABCD2 score ≥4; AND/OR crescendo TIA; AND/OR
already on dual antiplatelet therapy
• Index event is a non-cardioembolic ischemic stroke with:
○ Ongoing limb weakness OR ongoing facial weakness with
resolved limb weakness; AND/OR dysphasia; AND/OR
ongoing isolated hemianopia (with positive neuroimaging
evidence showing ischemic stroke in occipital lobe); AND
duration ≥one-hour
○ Resolved limb weakness; AND/OR dysphasia; AND
duration >24 h after onset (i.e. resolution between 24 h and
randomization)
• Willing and able to provide written informed consent; proxy
consent is acceptable if patients are dysphasic or confused, in
accordance with the practice of the local site
Exclusion criteria:
• Isolated sensory symptoms, facial weakness, or vertigo/dizziness
• Isolated hemianopia without positive neuroimaging evidence
• Intracranial haemorrhage
• Baseline neuroimaging shows intracranial haemorrhage or
parenchymal haemorrhagic transformation (PH 1 or 2) of infarct,
subarachnoid haemorrhage, or other non-ischemic cause for
symptoms
• Presumed cardioembolic stroke (e.g. history of current atrial
fibrillation (AF), myocardial infarction <three-months)
• Contraindications to, or intolerance of, aspirin, clopidogrel, or
dipyridamole
• Definite need for aspirin, clopidogrel, or dipyridamole indi-
vidually or in combination (e.g. aspirin and clopidogrel for recent
myocardial infarction (MI)/acute coronary syndrome)
• Definite need for full dose oral (e.g. apixaban, dabigatran, riva-
roxaban, warfarin) or medium to high dose parenteral (e.g.
heparin) anticoagulation
• Definite need for glycoprotein IIb/IIIa inhibitor
• No enteral access
• Pre-morbid dependency [modified Rankin Scale (mRS) > 2]
• Severe high BP (BP > 185/110 mmHg)
• Haemoglobin <100 g/l
• Platelet count <100 × 109/l or >600 × 109/l
• White cell count <3·5 × 109/l or >30 × 109/l
• Major bleeding within one-year (e.g. peptic ulcer, intracerebral
haemorrhage)
• Planned surgery in next three-months (e.g. known need for
carotid endarterectomy)
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• Concomitant acute coronary syndrome [e.g. ST segment eleva-
tion myocardial infarction (STEMI) or non-STEMI (NSTEMI)]
• Stroke secondary to a procedure (e.g. carotid or coronary
intervention)
• Coma [Glasgow Coma Scale (GCS) < 8]
• Non-stroke life expectancy <six-months
• Known dementia
• Women of childbearing potential, pregnant, or breastfeeding
• Geographical or other factors that may interfere with follow-up
• Patients who have not had post-thrombolysis neuroimaging
Patients may be enrolled concurrently into observational studies
or non-drug/device trials.
Baseline measures
Baseline demographic details (age, gender, race-ethnicity), pre-
morbid mRS, clinical details (syndrome (43)), stroke severity
[National Institutes of Health Stroke Scale, (NIHSS) (44)], BP, full
blood count, and electrocardiogram (ECG) are determined after
consent/assent and before randomization.
Neuroimaging – computerized tomography (CT) or magnetic
resonance (MR) scanning – is performed for patients with isch-
emic stroke to exclude intracranial haemorrhage and non-stroke
diagnoses. If thrombolysis is performed, CT/MR must be under-
taken afterward and prior to randomization to exclude haemor-
rhagic transformation. Patients presenting with a TIA do not have
to have a CT/MR as this reflects routine practice at many stroke
centers. Patients with cerebral events that occur during treatment
must also be re-scanned to identify potential secondary bleeding.
Local site reporting of scans is recorded; all scans are also
uploaded over the Internet for independent adjudication using a
validated structured classification system [as used in IST-3 and
Efficacy of Nitric Oxide in Stroke trial (ENOS)] (45–48) and
masked to treatment.
At baseline and day 7 ± 1, optional research blood samples may
be taken for substudies involving biomarkers and genetics; some
samples are centrifuged to collect plasma and serum, and then
frozen.
Randomization
All randomization, data collection, and serious adverse event
(SAE) and CT adjudication are performed over a secure
password-protected and data-encrypted Internet website: www-
.tardistrial.org. Patients are randomized in real time with:
Stratification on:
• Index event: stroke/TIA
• Country
Minimization on key prognostic baseline factors:
• Age: ≤70 vs. >70 years
• Gender: female, male
• Pre-morbid mRS: 0, >0
• Time, stroke/TIA to randomization: 24 vs. <24 h
• Number of antiplatelets before index event: 0/1, 2
• Clinical syndrome: lacunar (LACS/POCS), cortical (PACS/
TACS) (49)
• Systolic BP: ≤160, >160 mmHg
• Gastro-protection: yes, no
• Use of low dose heparin: no, yes
Additional minimization is performed if the index event is an
ischemic stroke:
• NIHSS: 0–3, >3
• Treatment with alteplase: yes, no
Additional minimization is performed if the index event is
a TIA:
• ABCD2 score: 0–5, >5
• Number of TIAs in last week: 0/1, >1
Simple randomization:
• In 5% of patients
Stratification and minimization allow for improved matching
at baseline, stratification allows variable categories to be treated as
trials in their own right, minimization increases statistical power
(50), and simple randomization reduces predictability.
Investigational medicinal products
Trial interventions are given open label for one-month (28 or 30
days depending on treatment pack size, to cover the period of
maximum risk of recurrence but minimize bleeding) and com-
prise (Fig. 1):
• Aspirin: loading dose 300 mg (51) then 50–150 mg daily; by
oral, nasogastric tube (NGT), or rectal route
• Clopidogrel: loading dose 300 mg (52) then 75 mg daily; by
oral or NGT route
• Dipyridamole: 225–450 mg in divided doses; by oral (as
200 mg extended release capsules twice daily (53), or as tablets
three to four times daily) or NGT (as suspension or crushed
tablets three to four times daily) route
Treatment groups comprise:
• Intensive/triple antiplatelets (active): Combined aspirin, clopi-
dogrel, and dipyridamole
• Guideline/dual or mono antiplatelet(s): Combined aspirin and
dipyridamole, or clopidogrel alone [monotherapy was added fol-
lowing a change in UK National Institute for Health and Care
Excellence (NICE) guidance (54)]
Sites choose in advance which guideline treatment regimen
they wish to use, a choice that is made separately for ischemic
stroke (IS) and TIA:
• Aspirin + dipyridamole, or clopidogrel (1:1)
• Aspirin + dipyridamole
• Clopidogrel
The principal investigator (PI) may change the choice of com-
parator at any stage during the trial with 48-h notice, that is, a
change cannot influence treatment for a patient who is in the
process of being enrolled.
Antiplatelet agents may be administered after the index stroke/
TIA event and before randomization as follows:
Fig. 1 Treatment (day 0–30) and follow-up (to day 90). A, aspirin; C,
clopidogrel; D, dipyridamole.
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• Aspirin may be given after the index event and prior to ran-
domization in any potential trial participant.
• Clopidogrel is only allowed if the patient may receive it as part
of the trial according to the PI’s choice of comparator, that is, the
patient can only be randomized to intensive antiplatelets vs. clopi-
dogrel alone.
• Dipyridamole (in combination with aspirin) is only allowed if
the patient may receive it as part of the trial according to the PI’s
choice of comparator, that is, the patient can only be randomized
to intensive antiplatelets vs. combined aspirin and dipyridamole.
• If the patient is given a ‘confounding’ antiplatelet after their
event and before randomization, the patient may still be included
but randomization will then only involve the appropriate com-
parison to prevent confounding of treatment.
Patients who have received combined clopidogrel and aspirin,
clopidogrel and dipyridamole, cilostazol (whether singly or in
combination), or triflusal (whether singly or in combination) are
excluded from the trial.
Study drugs may be stopped around procedures that become
necessary after enrollment; trial drugs should be re-started as soon
as possible after the procedure once clinically appropriate. Partici-
pants can be withdrawn from therapy either at their own request,
for safety reasons, or if unacceptable adverse events develop. After
the 28–30-day treatment period, participants are expected to
return to guideline antiplatelet therapy as recommended by local,
national, and international guidelines. Patients are also offered
standard ‘best care’ prophylaxis, including lifestyle advice, BP and
lipid-lowering drugs, and carotid endarterectomy (as necessary).
Primary outcome
The primary outcome is the frequency and severity of recurrent
strokes and TIA in participants who have a recurrent event, with
assessment at day 90. Severity is measured using a six-level
ordered categorical scale that incorporates the mRS:
• Fatal stroke/severe non-fatal stroke (mRS 4 or 5)/moderate
stroke (mRS 2 or 3)/mild stroke (mRS 0 or 1)/TIA/no
stroke-TIA¶
Ascertainment of recurrent events, and mRS, is determined
centrally by telephone by a trained assessor who is masked to
outcome at day 90 ± 7. To ensure recurrent events are identified,
corroborating information is sought from the general practitio-
ner and recruiting hospital site.
The effect of the intervention on the primary outcome will be
performed within the following subgroups:
(a) Geographical region: UK, other ¶
(b) Age: ≤70 years, >70 years ¶
(c) Gender: female, male
(d) mRS: 0, >0 ¶
(e) Index event: ischemic stroke, TIA
(f) Stroke/TIA syndrome: LACS, POCS, PACS, TACS (49) ¶
(g) Stroke/TIA etiology: small vessel disease (SVD), large artery
disease (LAD), other ¶
(h) NIHSS (stroke only): 0–3, >3 ¶
(i) ABCD2 score (TIA only): 0–5, >5 ¶
(j) Crescendo TIA (TIA only): no, yes ¶
(k) Number of antiplatelet agents at baseline: 0, 1, 2 ¶
(l) Type of comparator: AD, C, either ¶
(m) Systolic BP: ≤140, 141–160, >160 mmHg ¶
(n) Time, event to randomization >24, 12·1–24, ≤12 h ¶
(o) Use of low dose heparin: no, yes ¶
(p) Treated with alteplase prior to randomization (stroke only):
yes, no
(q) Gastroprotection: yes, no ¶
(r) Carotid stenosis (ipsilateral ≥50%): no, yes ¶
(s) Old lesion on baseline neuroimaging: no, yes ¶
Secondary, bleeding, and safety outcomes
Investigators assess secondary outcomes at days 7 ± 1 and 35 ± 3,
and on discharge from hospital (if admitted). The National Coor-
dinating Centre assesses secondary outcomes at day 90 ± 7 by a
telephone call between the patient (or carer) and an assessor
blinded to treatment. Reported outcomes (stroke, MI) and SAEs
are adjudicated by a member of the independent adjudicator
panel who is blinded to treatment.
Day 7 ¶
(a) Headache that required treatment or led to discontinuation
(b) Recurrent stroke or TIA
(c) Impairment (NIHSS, including death)
(d) Neurological deterioration (increase in NIHSS by four points
or more)
(e) Composite vascular event
(f) Venous thromboembolism
(g) Haemoglobin
(h) Bleeding
(i) SAEs
Day 35 (end of treatment)
(a) Headache that required treatment or led to discontinuation
(b) Recurrent stroke or TIA
(c) Impairment (NIHSS, including death)
(d) Neurological deterioration (increase in NIHSS by four points
or more)
(e) Composite vascular
(f) Myocardial infarction
(g) Venous thromboembolism
(h) Haemoglobin
(i) Bleeding
(j) SAEs
Hospital discharge (collected at discharge or if death in
hospital)
(a) Length of stay in hospital
(b) Discharge disposition (death/institution/home)
Day 90 (end of follow-up)
(a) Death: time todeath (censored at 110days) andbywhat cause
(b) Composite vascular
(c) Myocardial infarction (55)
(d) Venous thromboembolism
(e) Barthel Index (BI)
(f) Dead or disabled (BI < 60)
(g) Quality of life/Health Utility Score [derived from European
Quality of Life-5 Dimensions (EQ-5D)] (56) Δ
(h) Quality of life [European Quality of Life Visual Analog Scale
(EQ-VAS)] Δ
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(i) Telephone-Mini-Mental State Examination Δ
(j) Telephone Interview Cognition Scale-Modified Δ
(k) Verbal fluency (animal naming over one-minute) Δ
(l) Zung Depression Scale (mood) (57) Δ
(m) Disposition (death/institution/home)
(n) Bleeding – by site and severity (58)
(o) SAEs – by time, type, site, and severity (21)
Δ will not be collected if carer answers questions without
recourse to participant.
Sample size
TARDIS was designed with a start-up phase (funded by British
Heart Foundation, and assessing safety, feasibility, and tolerabil-
ity) and a main phase (funded by Health Technology Assessment,
and assessing safety and efficacy).
The null hypothesis (H0) is that intensive antiplatelets will not
alter the frequency and severity of stroke/TIA in participants with
previous ischemic stroke or TIA. The alternative hypothesis is that
the frequency and severity of stroke/TIA differ between those
participants randomized to intensive vs. guideline antiplatelets. A
total sample size (59,60) of 4100 (2050 per group) participants
with ischemic stroke or TIA is required, assuming:
• Overall significance (alpha) = 0·05
• Power (1-beta) = 0·90
• Odds ratio of 0·68 (equivalent to an odds ratio of 0·57 and
relative risk reduction = 0·31 for binary stroke)
• Distribution in outcome based on recurrent stroke and its
severity using mRS (based on data from n = 1460 participants
with a final outcome):
○ Fatal stroke, 0·55%/mRS 4 or 5, 0·55%/mRS 2 or 3, 1·30%/
mRS 0 or 1, 1·23%/TIA, 3·22%/no event, 93·15%
• Treatment crossovers = 5·0%
• Losses to follow-up = 2%
• Reduction of 20% for baseline covariate adjustment (61)
Statistical analyses
Analyses will be performed by intention-to-treat using binary
logistic regression for binary outcomes, ordinal logistic regression
for ordered categorical variables (including the primary
outcome), multiple regression for continuous variables, and Cox
proportional hazards regression for time-to-event data. Analyses
will be adjusted for stratification and minimization factors.
Detailed analysis plans are given in the Statistical Analysis Plan.
Study organization and oversight
TARDIS is an independent academic trial performed by an inter-
national collaborative group. The Trial Steering Committee pro-
vides oversight and strategic input, and comprises independent
members, grant applicants, and patient, sponsor, and funder rep-
resentatives; it meets twice yearly. An International Advisory
Committee meets annually and provides advice on national issues
including recruitment and follow-up. The Trial Management
Committee runs the trial on a day-to-day basis and is based at the
TARDIS Trial Coordinating Centre in Nottingham. A National
Coordinating Centre and national coordinator are based in each
participating country. Outcomes, SAEs, and brain imaging are
adjudicated by trained assessors masked to treatment assignment.
The independent Data Monitoring Committee reviews
unblinded data twice yearly in respect of safety and efficacy, and
review recruitment, baseline data, balance in baseline factors
between the treatment groups, completeness of data, compliance
to treatment, co-administered treatments, outcome by subgroups,
SAEs (both adjudicated and unadjudicated), and protocol viola-
tions. They also take findings in the context of other published
evidence.
Research governance
TARDIS is conducted in accordance with the ethics and principles
enshrined in the Declaration of Helsinki and good clinical prac-
tice, and is run in accordance with the UK Medicines for Human
Use Regulations and Health Research Governance Framework.
The management of personal data adheres to the UK Data Pro-
tection Act (1998). The trial has approval from the Medicines and
Healthcare Products Regulatory Agency (reference 03057/0027/
001-0001, date 17/10/2008), Eudract number 2007-006749-21,
and National Research Ethics Committee (Reference 08/H1102/
112, date 9/1/2009). All sites have local Research Ethics Commit-
tee (REC) and NHS Research and Development (R&D)
approvals. The trial is registered with Current Controlled Trials
(ISRCTN47823388) and has been adopted by the UK NIHR
Stroke Research Network, and endorsed by the Australasian
Stroke Trials Network.
Summary and conclusions
TARDIS is addressing a key issue in the management of patients
with acute stroke and TIA, namely the safety and efficacy of
short-term intensive (combined aspirin, clopidogrel, and dipyri-
damole) vs. guideline antiplatelet therapy. The primary outcome
is the frequency and severity of stroke recurrence; TARDIS is the
first trial to use this novel end-point. The sample size of 4100
patients means that a modest but worthwhile clinical effect can be
detected with high statistical power (90%); to date, 2399 patients
have been recruited from 104 sites in 4 countries, with one-third
presenting with a TIA. A positive trial would mean that triple
antiplatelet therapy could be introduced rapidly into clinical
practice as the drugs are already licensed, readily available, and
inexpensive. We invite centers from around the world to join this
important collaborative international venture.
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